Verges B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;58(5):886–99. https://doi.org/10.1007/s00125-015-3525-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–53. https://doi.org/10.1093/eurheartj/ehq386.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Surma S, Sosnowska B, Reiner Z, Banach M. New data allow to better understand the secrets of lipoprotein(a): is that for sure? Eur Heart J Open. 2024;4(5):oeae066. https://doi.org/10.1093/ehjopen/oeae066.

Article  PubMed  PubMed Central  Google Scholar 

Toth PP. Familial hypercholesterolemia and lipoprotein(a): unraveling the knot that binds them. J Am Coll Cardiol. 2020;75(21):2694–7. https://doi.org/10.1016/j.jacc.2020.04.003.

Article  PubMed  Google Scholar 

Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med. 2013;273(1):6–30. https://doi.org/10.1111/j.1365-2796.2012.02592.x.

Article  CAS  PubMed  Google Scholar 

Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. 2022;42(1):e48-60. https://doi.org/10.1161/ATV.0000000000000147.

Article  CAS  PubMed  Google Scholar 

Edelstein C, Pfaffinger D, Hinman J, Miller E, Lipkind G, Tsimikas S, et al. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem. 2003;278(52):52841–7. https://doi.org/10.1074/jbc.M310425200.

Article  CAS  PubMed  Google Scholar 

Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement. Eur Heart J. 2022;43(39):3925–46. https://doi.org/10.1093/eurheartj/ehac361.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raschi E, Casula M, Cicero AFG, Corsini A, Borghi C, Catapano A. Beyond statins: new pharmacological targets to decrease LDL-cholesterol and cardiovascular events. Pharmacol Ther. 2023;250:108507. https://doi.org/10.1016/j.pharmthera.2023.108507.

Article  CAS  PubMed  Google Scholar 

Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther. 2013;35(8):1082–98. https://doi.org/10.1016/j.clinthera.2013.06.019.

Article  CAS  PubMed  Google Scholar 

Sahebkar A, Watts GF. New therapies targeting ApoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? Cardiovasc Drugs Ther. 2013;27(6):559–67. https://doi.org/10.1007/s10557-013-6479-4.

Article  CAS  PubMed  Google Scholar 

Bahrami A, Parsamanesh N, Atkin SL, Banach M, Sahebkar A. Effect of statins on toll-like receptors: a new insight to pleiotropic effects. Pharmacol Res. 2018;135:230–8. https://doi.org/10.1016/j.phrs.2018.08.014.

Article  CAS  PubMed  Google Scholar 

Chrusciel P, Sahebkar A, Rembek-Wieliczko M, Serban MC, Ursoniu S, Mikhailidis DP, et al. Impact of Statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194–208. https://doi.org/10.1016/j.atherosclerosis.2016.07.897.

Article  CAS  PubMed  Google Scholar 

Mollazadeh H, Tavana E, Fanni G, Bo S, Banach M, Pirro M, et al. Effects of statins on mitochondrial pathways. J Cachexia Sarcopenia Muscle. 2021;12(2):237–51. https://doi.org/10.1002/jcsm.12654.

Article  PubMed  PubMed Central  Google Scholar 

Parizadeh SM, Azarpazhooh MR, Moohebati M, Nematy M, Ghayour-Mobarhan M, Tavallaie S, et al. Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids. 2011;46(4):333–40. https://doi.org/10.1007/s11745-010-3517-x.

Article  CAS  PubMed  Google Scholar 

Sahebkar A, Foroutan Z, Katsiki N, Jamialahmadi T, Mantzoros CS. Ferroptosis, a new pathogenetic mechanism in cardiometabolic diseases and cancer: is there a role for statin therapy? Metabolism. 2023;146:155659. https://doi.org/10.1016/j.metabol.2023.155659.

Article  CAS  PubMed  Google Scholar 

Sahebkar A, Serban C, Ursoniu S, Mikhailidis DP, Undas A, Lip GY, et al. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost. 2016;115(3):520–32. https://doi.org/10.1160/TH15-08-0620.

Article  PubMed  Google Scholar 

de Pablos-Velasco P. Pioglitazone: beyond glucose control. Expert Rev Cardiovasc Ther. 2010;8(8):1057–67. https://doi.org/10.1586/erc.10.98.

Article  PubMed  Google Scholar 

Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother. 2008;9(7):1087–108. https://doi.org/10.1517/14656566.9.7.1087.

Article  CAS  PubMed  Google Scholar 

Alhowail AH, Aldubayan MA, Almami IS. Comparison of Pioglitazone and galantamine in preventing doxorubicin-induced glutamate receptors mRNA overexpression. Int J Pharmacol. 2023;19(8):925–30. https://doi.org/10.3923/ijp.2023.925.930.

Article  CAS  Google Scholar 

Alhowail AH, Aldubayan MA, Alenezi SK, Alyahya DI, Alhumaidi HS, Alqarawi LH, et al. Pioglitazone mitigates the toxic effect of doxorubicin-induced nephrotoxicity. Int J Pharmacol. 2024;20(8):1398–403. https://doi.org/10.3923/ijp.2024.1398.1403.

Article  Google Scholar 

RadenkoviĆ M. Pioglitazone and endothelial dysfunction: pleiotropic effects and possible therapeutic implications. Sci Pharm. 2014. https://doi.org/10.3797/scipharm.1407-16.

Article  PubMed  PubMed Central  Google Scholar 

Betteridge DJ. Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab. 2007;9(5):640–7. https://doi.org/10.1111/j.1463-1326.2007.00715.x.

Article  CAS  PubMed  Google Scholar 

Liao HW, Saver JL, Wu YL, Chen TH, Lee M, Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open. 2017;7(1):e013927. https://doi.org/10.1136/bmjopen-2016-013927.

Article  PubMed  PubMed Central  Google Scholar 

Kaku K, Daida H, Kashiwagi A, Yamashina A, Yamazaki T, Momomura S, et al. Long-term effects of Pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. Curr Med Res Opin. 2009;25(12):2925–32. https://doi.org/10.1185/03007990903328124.

Article  CAS  PubMed  Google Scholar 

Investigators OT, Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28. https://doi.org/10.1056/NEJMoa1203858.

Article  CAS  Google Scholar 

Ramandi A, Diehl AM, Sanyal AJ, de Jong YP. Experimental models to investigate PNPLA3 in liver steatosis. Liver Int. 2025;45(5):e70091.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Romeo S, Valenti L. Fifteen years of PNPLA3: transforming hepatology through human genetics. Liver Int. 2025;45(9):e70240.

Article  PubMed  PubMed Central